These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 16381057)

  • 21. Dose finding - a challenge in statistics.
    Bretz F; Hsu J; Pinheiro J; Liu Y
    Biom J; 2008 Aug; 50(4):480-504. PubMed ID: 18663758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluating potential benefits of dose-exposure-response modeling for dose finding.
    Hsu CH
    Pharm Stat; 2009; 8(3):203-15. PubMed ID: 19629954
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of dose-finding designs for narrow-therapeutic-index drugs: concentration-controlled vs. dose-controlled trials.
    Lledó-García R; Hennig S; Karlsson MO
    Clin Pharmacol Ther; 2009 Jul; 86(1):62-9. PubMed ID: 19339964
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Designs for phase I clinical trials with multiple courses of subjects at different doses.
    Fan SK; Wang YG
    Biometrics; 2007 Sep; 63(3):856-64. PubMed ID: 17403103
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios.
    Yin G; Li Y; Ji Y
    Biometrics; 2006 Sep; 62(3):777-84. PubMed ID: 16984320
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction approaches to sequentially searching for an optimal dose.
    Shih WJ
    Biometrics; 1989 Jun; 45(2):623-8. PubMed ID: 2669990
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of dose-response in flexible dose titration clinical studies.
    Xu XS; Yuan M; Nandy P
    Pharm Stat; 2012; 11(4):280-6. PubMed ID: 22407972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Commentary on 'Designs for dose-escalation trials with quantitative responses'.
    Senn S
    Stat Med; 2009 Dec; 28(30):3754-8; discussion 3759-60. PubMed ID: 19967754
    [No Abstract]   [Full Text] [Related]  

  • 29. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.
    Buckley LA; Dorato MA
    Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A placebo arm is not always necessary in clinical trials of amyotrophic lateral sclerosis.
    Gordon PH
    Muscle Nerve; 2009 Jun; 39(6):858-60. PubMed ID: 19382169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety evaluation to support First-In-Man investigations II: toxicology studies.
    Baldrick P
    Regul Toxicol Pharmacol; 2008 Jul; 51(2):237-43. PubMed ID: 18501490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A parallel phase I/II clinical trial design for combination therapies.
    Huang X; Biswas S; Oki Y; Issa JP; Berry DA
    Biometrics; 2007 Jun; 63(2):429-36. PubMed ID: 17688495
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method.
    Normolle D; Lawrence T
    J Clin Oncol; 2006 Sep; 24(27):4426-33. PubMed ID: 16983110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A note on multiple testing procedures in dose finding.
    Bauer P
    Biometrics; 1997 Sep; 53(3):1125-8. PubMed ID: 9333343
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose-escalation designs in oncology: ADEPT and the CRM.
    Shu J; O'Quigley J
    Stat Med; 2008 Nov; 27(26):5345-53; discussion 5354-5. PubMed ID: 18752259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adaptive designs for dose-finding in non-cancer phase II trials: influence of early unexpected outcomes.
    Resche-Rigon M; Zohar S; Chevret S
    Clin Trials; 2008; 5(6):595-606. PubMed ID: 19029208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design of phase II ALS clinical trials.
    Schoenfeld DA; Cudkowicz M
    Amyotroph Lateral Scler; 2008; 9(1):16-23. PubMed ID: 18273715
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A test for differences between treatment means when several dose levels are compared with a zero dose control.
    Williams DA
    Biometrics; 1971 Mar; 27(1):103-17. PubMed ID: 5547548
    [No Abstract]   [Full Text] [Related]  

  • 39. Two-stage design for dose-finding that accounts for both efficacy and safety.
    Dragalin V; Fedorov VV; Wu Y
    Stat Med; 2008 Nov; 27(25):5156-76. PubMed ID: 18680164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New adaptive method for phase I trials in oncology.
    Meille C; Gentet JC; Barbolosi D; André N; Doz F; Iliadis A
    Clin Pharmacol Ther; 2008 Jun; 83(6):873-81. PubMed ID: 17957185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.